DanaMarieRoqueMD

Gynecologic Oncology

Associate Professor, Gynecologic Oncology, University of Maryland-Greenebaum Cancer Center; Director, Center of Excellence in Minimally Invasive Gynecology

Join to view full profile

Dr. Roque is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Roque's full profile

Already have an account?

Office
University of Maryland Medical Center
22 S Greene St
Baltimore, MD 21201
Phone+1 410-328-2076

Fax+1 410-328-8389

Education & Training

Yale-New Haven Medical CenterFellowship, Gynecologic Oncology, 2011 - 2014
UPMC Medical EducationResidency, Obstetrics and Gynecology, 2007 - 2011
University of North Carolina at Chapel Hill School of MedicineClass of 2007

Certifications & Licensure

MD State Medical License 2014 - 2025
CT State Medical License 2011 - 2015
PA State Medical License 2007 - 2012
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab Start of enrollment: 2017 Apr 03
Completed
Phase 2

Publications & Presentations

PubMed

Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT030931...
Dana M Roque, Eric R Siegel, Natalia Buza, Stefania Bellone, Gloria S Huang
BJC Reports. 2024-06-20
Early Implementation of Robotic Training in Surgical and Surgical Subspecialty Residency.
John J Newland, Margaret H Sundel, Kyle W Blackburn, Cassandra A Cairns, Laura E Cooper
The American Surgeon. 2024-06-01
Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
Dana M Roque, Eric R Siegel, Natalia Buza, Stefania Bellone, Dan-Arin Silasi
British Journal of Cancer. 2024-04-01

Press Mentions

New Study Reveals a Two-Drug Combination to Fight Malignant Ovarian CancerFebruary 15th, 2022
Yale Cancer Center Led Research Shows New Drug Combination Effective for Patients with Advanced Ovarian CancerFebruary 14th, 2022
Combo Tx Active in Recurrent, Platinum-Resistant Ovarian CancerMarch 26th, 2021